Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination
NCT ID: NCT03842631
Last Updated: 2019-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2019-02-16
2020-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China
NCT03173352
Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
NCT00374335
Optical Tomographic Imaging of Infantile Hemangiomas
NCT01673971
A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas
NCT01598116
Propranolol in Capillary Hemangiomas
NCT00744185
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Superficial Group
Hemangioma depth evaluated by B-ultrasonoscope is lower than or equal to 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
Timolol Maleate 0.5% Oph Soln
External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
Deep Group
Hemangioma depth evaluated by B-ultrasonoscope is more than 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
Timolol Maleate 0.5% Oph Soln
External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Timolol Maleate 0.5% Oph Soln
External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Skin Infantile hemangiomas (IHs) in the proliferation stage without prior treatment
* IHs with a surface area of less than 1% of body surface area
* Skin type III/IV
Exclusion Criteria
* Unsuitable for topical Timolol treatment due to anatomical location of lesion, eg.
periorbital and lip IHs.
* Patients with severe systemic or congenital disease which may affect the patient's safety in this study
6 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
XiaoXi Lin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
XiaoXi Lin
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaoxi Lin, PhD
Role: PRINCIPAL_INVESTIGATOR
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Ninth People's hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SH9H-2018-T48-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.